Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa

• https://x.com/RichardPAConway/status/1983234558985417164/photo/1

IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172 https://t.co/xC3wgaN9bk

• https://x.com/Janetbirdope/status/1983233945102659935/photo/1

After melanoma, should RA patients stop DMARDs? These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma #ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln

• https://x.com/drdavidliew/status/1983229116469162290/photo/1

#IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We

• https://x.com/Janetbirdope/status/1983227740267422026/photo/1
• https://x.com/Janetbirdope/status/1983227740267422026/photo/1

Infection vs steroid sparing in PMR/GCA/AAV studies with steroid-sparing Rx GiACTA (1, top right) aside, - low infection rates - the more steroid saved, the less the infection risk Infection risk in vasculitis is driven by steroid, not DMARD #ACR25 ABST2526 @RheumNow https://t.co/UprbxUQyQC

• https://x.com/drdavidliew/status/1983221326518026404/photo/1

Data from this retrospective cohort study by Alomari et al show that SLE pts on SGLT2is ⬇️rates of PulHPN (OR 0.79) ⬇️all-cause mortality (0.49) ⬇️hospitalizations (OR 0.56) ⬇️LN (OR 0.4) vs non-SGLT2i users(p<0.001) Impt role of SGLT2i as adjunct tx #ACR25 @RheumNow Abs2438 https://t.co/NQJTzQwRCt

• https://x.com/RHEUMarampa/status/1983215936154022119/photo/1

Post hoc eval of relapses from MANDARA, MEPO vs BEN in EGPA 30% of pts had relapse, 81% of which were asthma +/- sinonasal disease Remainder were mostly muscle involved, only a few mononeuritis Mostly as expected; useful epi data for clinic #ACR25 @RheumNow Abstr#1769 https://t.co/IKKolMZJlF

• https://x.com/EBRheum/status/1983209393299619853/photo/1
• https://x.com/EBRheum/status/1983209393299619853/photo/1
• https://x.com/EBRheum/status/1983209393299619853/photo/1

Hindosh et al. Semaglutide associated with reduced synovitis, joint pain and swelling, in RA. @RheumNow #ACR25 Abstr#2286 https://t.co/6Xs4um5l32

• https://x.com/RichardPAConway/status/1983201088410136955/photo/1

Bremer et al. Earlier initiation of biosimilar adalimumab (vs csDMARDs) may result in cost-savings. Reduced cost of tests, consultations, and hospitalisations. @RheumNow #ACR25 Abstr#2271 https://t.co/lHaSiX3WLd

• https://x.com/RichardPAConway/status/1983200333644902456/photo/1

Is taking NSAIDs +TNFi better for the joints? Abstract 2359: In radiographic axSpA, NSAIDS + TNFi associated with -fewer syndesmophytes 36% vs 58% TNFi - no significant effect on hip structural changes - @RheumNow #ACR25

CD19 counts during RTX maintenance therapy do NOT perform well in assessing the risk of relapse Interestingly, only younger age was associated with relapse in this retrospective study @RheumNow #ACR25 Abst 1766 https://t.co/crsFKJ0LnP

• https://x.com/Dr_Brian_MD/status/1983197370197446827/photo/1

Zavada et al. 52 patients. bDMARD therapy improves sexual function at 6 months in r-axSpA. Improvements in function, desire, satisfaction in those with baseline erectile dysfunction @RheumNow #ACR25 Abstr#2346 https://t.co/IUMGCFnXZh

• https://x.com/RichardPAConway/status/1983196810190696712/photo/1

Konsta et al. Adding NSAID to TNF inhibits spinal but not hip radiograpic progress. 262 patients, TNF+NSAID 100, TNF alone 162. New syndesmophytes 36% vs 58%. ΔmSASSS-score/year 0.1 vs 0.7. No effect on progression of hip radiographs. @RheumNow #ACR25 Abstr#2359 #ACRBest https://t.co/k9j2M2E3ze

• https://x.com/RichardPAConway/status/1983196307096297889/photo/1

Paging the pharmacist Abstract 1973: Dedicated clinic pharmacist -> benefits Tasks included: 🔹 74% PA support 🔹 55% patient education 🔹 40% medication management ~50% pts had clinically meaningful improvement Providers report ↑ care quality & ↓ admin burden @RheumNow #ACR25

MAINRITSEG: RTX vs. AZA for maintenance in EGPA RTX not superior in primary remission outcome RTX favored in secondary outcome of remission with pred <4mg daily Limitation: only ~50% pt with FFS 1+ @RheumNow #ACR25 Abst 1765 https://t.co/dh5ZWCT12T

• https://x.com/Dr_Brian_MD/status/1983195125145911381/photo/1